{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Protocol-Amendments-and-Regulatory-Notifications”
},
“headline”: “SOP for Protocol Amendments and Regulatory Notifications in Clinical Trials”,
“description”: “A regulatory-compliant SOP detailing the step-by-step process for managing clinical trial protocol amendments and regulatory notifications as per ICH GCP, WHO, FDA, EMA, and CDSCO requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 23/12/2025
Standard Operating Procedure for Protocol Amendments and Regulatory Notifications in Clinical Trials
| Department | Clinical Research |
| SOP No. | CR/REG/002/2025 |
| Supersedes | NA |
| Page No. | 1 of 20 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to describe the process for preparing, reviewing, submitting, and tracking clinical trial protocol amendments and associated regulatory notifications. This ensures compliance
Scope
This SOP applies to all clinical research staff, investigators, regulatory affairs personnel, and quality assurance teams involved in protocol amendments and regulatory notifications for ongoing or planned clinical trials. It covers both substantial amendments (those impacting patient safety, trial conduct, or data integrity) and non-substantial amendments.
Responsibilities
- Principal Investigator (PI): Initiates protocol amendment requests and ensures scientific justification.
- Regulatory Affairs Manager: Prepares and submits amendment packages to regulatory authorities and ethics committees.
- Clinical Research Associate (CRA): Communicates changes to site staff and ensures implementation.
- Quality Assurance Officer: Verifies compliance of amendments with regulatory requirements.
- Head of Clinical Research: Approves protocol changes prior to submission.
Accountability
The Regulatory Affairs Head is accountable for ensuring all amendments and notifications are submitted accurately and within the defined timelines. Failure to notify may result in regulatory non-compliance, trial suspension, or penalties.
Procedure
1. Identification of Amendment Requirement
Determine if proposed changes qualify as substantial (e.g., changes to trial endpoints, dosage, inclusion/exclusion criteria) or non-substantial (e.g., administrative corrections).
Document rationale for amendment in an Amendment Request Form.
2. Preparation of Amendment Dossier
Update the Clinical Trial Protocol with tracked changes.
Revise associated documents (e.g., Informed Consent Form, Investigator’s Brochure).
Compile country-specific forms and cover letters.
Ensure updated safety information is included, if applicable.
3. Internal Review and Approval
Submit amendment dossier to QA for compliance review.
Obtain internal approvals from the Head of Clinical Research.
Maintain version control and document history.
4. Submission to Regulatory Authority and Ethics Committee
Submit amendment electronically via eCTD or as required by local authority.
Notify the Ethics Committee/IRB with complete amendment dossier.
Ensure acknowledgment of submission is filed in the Regulatory Communication Log.
5. Notification to Sites and Investigators
Provide site staff with revised protocol and training, if applicable.
Ensure investigators sign acknowledgment of receipt of updated documents.
6. Documentation and Archiving
File all amendment-related documents in the Trial Master File (TMF).
Maintain amendment tracking log for audit readiness.
Abbreviations
- SOP: Standard Operating Procedure
- PI: Principal Investigator
- CRA: Clinical Research Associate
- QA: Quality Assurance
- eCTD: Electronic Common Technical Document
- TMF: Trial Master File
- EC/IRB: Ethics Committee/Institutional Review Board
Documents
- Amendment Request Form (Annexure-1)
- Amendment Tracking Log (Annexure-2)
- Regulatory Communication Log (Annexure-3)
References
- ICH E6(R2) Good Clinical Practice
- US FDA Guidance on Protocol Amendments
- EMA Clinical Trial Regulation (EU No. 536/2014)
- WHO Good Clinical Practice Guidelines
- CDSCO Clinical Trial Rules, India (2019)
Version: 1.0
Approval Section
| Prepared By | Rajesh Kumar, Regulatory Affairs Specialist |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Head of Clinical Research |
Annexures
Annexure-1: Amendment Request Form
| Date | Protocol No. | Description of Amendment | Reason | Initiated By |
|---|---|---|---|---|
| 01/09/2025 | CTP-2025-01 | Change in dosing frequency | Safety findings | Dr. Meera Joshi |
Annexure-2: Amendment Tracking Log
| Amendment No. | Date Submitted | Submitted To | Status | Remarks |
|---|---|---|---|---|
| 01 | 05/09/2025 | EMA | Under review | Additional safety data requested |
Annexure-3: Regulatory Communication Log
| Date | Authority | Query | Response | Responsible Person |
|---|---|---|---|---|
| 12/09/2025 | FDA | Clarification on inclusion criteria | Submitted revised section | Rajesh Kumar |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head, Clinical Research |
For more SOPs visit: Pharma SOP